Dianthus Therapeutics DNTH EBITDA

EBITDA at other companies

Johnson & JohnsonJNJ

$9.1B+5.9%

AmgenAMGN

$4.63B+15.7%

AnaptysBio, Inc.ANAB

-$34.51M-26.0%

Vor BiopharmaVOR

-$35.13M-8.2%

Cullinan Therapeutics, Inc.CGEM

-$57.18M+24.5%

Shattuck Labs, Inc.STTK

-$15.3M-26.4%

FAQ

What is Dianthus Therapeutics's EBITDA?

Dianthus Therapeutics (DNTH) reported EBITDA of -$46.5M in Q1 2026.

How has Dianthus Therapeutics's EBITDA changed year-over-year?

Dianthus Therapeutics's EBITDA decreased by 40.3% year-over-year, from -$33.15M to -$46.5M.

What is the long-term trend for Dianthus Therapeutics's EBITDA?

Over 3 years (2021 to 2024), Dianthus Therapeutics's EBITDA has grown at a 11.9% compound annual growth rate (CAGR), from -$72.67M to -$101.77M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.